-
EP4262801
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4262801
| EP4262801 - MASITINIB FOR THE TREATMENT OF ALZHEIMER'S DISEASE [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 22.09.2023 Database last updated on 22.08.2024 | |
| Former | The international publication has been made Status updated on 25.06.2022 | ||
| Former | unknown Status updated on 17.01.2022 | Most recent event Tooltip | 23.02.2024 | Change: Validation states | published on 27.03.2024 [2024/13] | 23.02.2024 | Change - extension states | published on 27.03.2024 [2024/13] | Applicant(s) | For all designated states AB Science 3, avenue George V 75008 Paris / FR | [2023/43] | Inventor(s) | 01 /
MOUSSY, Alain 75006 Paris / FR | 02 /
MANSFIELD, Colin 14280 Saint-Contest / FR | [2023/43] | Representative(s) | Icosa 83 avenue Denfert-Rochereau 75014 Paris / FR | [2023/43] | Application number, filing date | 21839188.6 | 16.12.2021 | [2023/43] | WO2021EP86308 | Priority number, date | EP20200306589 | 16.12.2020 Original published format: EP 20306589 | [2023/43] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022129410 | Date: | 23.06.2022 | Language: | EN | [2022/25] | Type: | A1 Application with search report | No.: | EP4262801 | Date: | 25.10.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 23.06.2022 takes the place of the publication of the European patent application. | [2023/43] | Search report(s) | International search report - published on: | EP | 23.06.2022 | Classification | IPC: | A61K31/496, A61P25/28 | [2023/43] | CPC: |
A61K31/496 (EP,IL,US);
A61K31/497 (KR);
A61K31/13 (US);
A61K31/27 (US);
A61K31/44 (US);
A61K31/55 (US);
A61P25/28 (KR,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/43] | Title | German: | MASITINIB ZUR BEHANDLUNG VON MORBUS ALZHEIMER | [2023/43] | English: | MASITINIB FOR THE TREATMENT OF ALZHEIMER'S DISEASE | [2023/43] | French: | MASITINIB POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER | [2023/43] | Entry into regional phase | 17.07.2023 | National basic fee paid | 17.07.2023 | Designation fee(s) paid | 17.07.2023 | Examination fee paid | Examination procedure | 27.06.2023 | Amendment by applicant (claims and/or description) | 17.07.2023 | Examination requested [2023/43] | 17.07.2023 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 28.12.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X] - FRANÃ OIS PIETTE ET AL, "Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial", ALZHEIMERS RES THER, BIOMED CENTRAL LTD, LONDON, UK, (20110419), vol. 3, no. 2, doi:10.1186/ALZRT75, ISSN 1758-9193, page 16, XP021102296 [X] 1-15 * figure 2; tables 1, 2 * DOI: http://dx.doi.org/10.1186/alzrt75 | by applicant | EP1525200 | WO2008098949 | US7423055 | - ROSEN et al., Am J Psychiatry, (19841100), vol. 141, no. 11, pages 1356 - 64 | - GALASKO et al., Alzheimer Dis Assoc Disord, (19970000), vol. 11, pages 33 - 9 | - FOLSTEIN et al., J Psychiatr Res, (19751100), vol. 12, no. 3, pages 189 - 98 | - CAS , no. 1048007-93-7 |